Insider · CIK 0001422304

Henderson Jane

CIK 0001422304 Name as filed on the most recent filing

Filed as Henderson Jane (18)

31 transaction lines · from 18 filings · filed 2008-05-05 to 2026-05-04 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

31 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2026-05-01 S, Open-market sale Apogee Therapeutics, Inc.APGE 3 lines 164,080, disposed Open Form 4 filing 0001104659-26-055091
2026-04-16 S, Open-market sale Apogee Therapeutics, Inc.APGE 180,000, disposed Open Form 4 filing 0001104659-26-045062
2026-04-01 S, Open-market sale Apogee Therapeutics, Inc.APGE 2 lines 170,020, disposed Open Form 4 filing 0001104659-26-039708
2026-03-25 S, Open-market sale Apogee Therapeutics, Inc.APGE 170,000, disposed Open Form 4 filing 0001104659-26-036332
2026-03-02 S, Open-market sale Apogee Therapeutics, Inc.APGE 4 lines 140,431, disposed Open Form 4 filing 0001104659-26-023651
2026-02-02 S, Open-market sale Apogee Therapeutics, Inc.APGE 3 lines 131,630, disposed Open Form 4 filing 0001104659-26-010453
2026-01-06 S, Open-market sale Apogee Therapeutics, Inc.APGE 160,000, disposed Open Form 4 filing 0001104659-26-001483
2026-01-02 S, Open-market sale Apogee Therapeutics, Inc.APGE 2 lines 449,146, disposed Open Form 4 filing 0001104659-26-001483
2025-12-19 S, Open-market sale Apogee Therapeutics, Inc.APGE 120,000, disposed Open Form 4 filing 0001104659-25-124354
2025-12-04 S, Open-market sale Apogee Therapeutics, Inc.APGE 112,500, disposed Open Form 4 filing 0001104659-25-118985
2025-11-25 S, Open-market sale Apogee Therapeutics, Inc.APGE 105,000, disposed Open Form 4 filing 0001104659-25-117036
2025-11-14 S, Open-market sale Apogee Therapeutics, Inc.APGE 130,000, disposed Open Form 4 filing 0001104659-25-112825
2025-11-11 S, Open-market sale Apogee Therapeutics, Inc.APGE 60,000, disposed Open Form 4 filing 0001104659-25-111631
2025-08-12 S, Open-market sale Akero Therapeutics, Inc.AKRO 142,371, disposed Open Form 4 filing 0000950170-25-107545
2024-08-23 S, Open-market sale Apogee Therapeutics, Inc.APGE 289,560, disposed Open Form 4 filing 0001104659-24-092519
2023-06-16 S, Open-market sale Akero Therapeutics, Inc.AKRO 2 lines 2,166,685, disposed Open Form 4 filing 0000950170-23-029228
2018-03-23 S, Open-market sale Voyager Therapeutics, Inc.VYGR 229,824, disposed Open Form 4 filing 0001104659-18-020100
2018-03-22 S, Open-market sale Voyager Therapeutics, Inc.VYGR 419,293, disposed Open Form 4 filing 0001104659-18-020100
2018-03-19 S, Open-market sale Voyager Therapeutics, Inc.VYGR 41,344, disposed Open Form 4 filing 0001104659-18-019018
2018-03-16 S, Open-market sale Voyager Therapeutics, Inc.VYGR 341,464, disposed Open Form 4 filing 0001104659-18-019018
2008-04-30 P, Open-market purchase Panacos Pharmaceuticals, Inc.PANC 23,535, acquired Open Form 4 filing 0001181431-08-028633

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase
Relationships on this page
O, Officer
Officer
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 1
  • Open-market sale 30
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Henderson Jane, insider transactions. Retrieved 2026-08-23 from https://ebomi.com/insider/0001422304

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.